Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer

Johnson & Johnson

BEERSE, BELGIUM , Oct. 24, 2026 -- Johnson & Johnson today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localised or locally advanced prostate cancer.1 The apalutamide plus hormone therapy regimen reduced the risk of disease recurrence or death by 62% compared with surgery alone.1 The regimen also showed a nominal improvement in metastasis-free survival (MFS), with a 51% lower risk of metastasis or death.1 Patients receiving perioperative treatment also experienced longer time to subsequent therapy compared with surgery alone.1

  1. Johnson & JohnsonJohnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancerCompanies: Johnson & JohnsonNew substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared...
  2. Le CHMP recommande l’approbation de TALVEY®▼ (talquetamab) de Johnson & Johnson, en association avec le daratumumab, dans une ligne de traitement plus précoce du myélome multiple en rechute/réfractaireCompanies: Johnson & JohnsonBEERSE, BELGIQUE, 23 oct. 2026 -- Johnson & Johnson, leader mondial du traitement du myélome multiple, annonce ce jour que le Comité des médicaments à usage humain (ou CHMP, de l’anglais Committee for Medicinal Products for Human Use) de l’Agence européenne des médicaments (AEM) a émis un avis favorable à l’extension de l’indication de TALVEY® (talquetamab). Cette recommandation porte sur l’utilisation du talquetamab en association avec le daratumumab, avec ou sans pomalidomide, chez les patients adultes atteints d’un myélome multiple en rechute ou réfractaire (MMRR) ayant reçu au moins une ligne de traitement antérieure.
  3. Il CHMP raccomanda l'approvazione di TALVEY®▼ (talquetamab) di Johnson & Johnson in combinazione con daratumumab nel trattamento in una linea terapeutica più precoce del mieloma multiplo recidivante/refrattarioCompanies: Johnson & JohnsonJohnson & Johnson, leader in tutto il mondo nell'ambito del mieloma multiplo, ha annunciato oggi che il Comitato per i Medicinali per Uso Umano (CHMP) dell'Agenzia europea per i medicinali (EMA) raccomanda l'approvazione di un'estensione dell'indicazione di TALVEY® (talquetamab). La raccomandazione riguarda talquetamab in combinazione con daratumumab, con o senza pomalidomide, per il trattamento di pazienti adulti con mieloma multiplo recidivante o refrattario (RRMM) che hanno ricevuto almeno una precedente linea di terapia.
  4. Government & policyEuropean Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapseCompanies: Johnson & JohnsonJohnson & Johnson, a worldwide leader in multiple myeloma, today announced that the European Commission (EC) has approved an indication extension of TECVAYLI® (teclistamab) for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy. Building on the recent EC approval of teclistamab plus daratumumab, this indication extension introduces teclistamab monotherapy as an additional second-line treatment option for patients living with RRMM and reinforces the wider potential of teclistamab across both monotherapy and combination approaches for patients at first relapse.1,2
  5. AIGlobal Life Science Market Report 2026: Size, Trends and Forecast to 2030 | Secure $200.6B AI and Precision Medicine Upside with Johnson & Johnson, Roche, Pfizer, and AstraZenecaCompanies: Johnson & JohnsonAstraZenecaPfizerRoche Holding"Life Science Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  6. 小売特化ハイブリッドクラウドPOSレジ「poscm_plus」がリファンド方式に対応！株式会社 J&J Tax Free社と連携が可能にCompanies: Johnson & Johnson[株式会社ウェブベース] 株式会社ウェブベース（本社：大阪府豊中市、代表取締役社長 兼 CEO：野口 聡之 、以下「当社」）が提供する小売特化ハイブリッドクラウドPOSレジ「poscm_plus（ポスカムプラス）」（以下、poscm_plus）は、株式...